Cancer clinical trials in the region Auvergne-Rhône-Alpes

498 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes

Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Brain tumors / Central nervous system tumors #NCT04702581
Required histologic types
Gliomas
Required histologic sub types
Oligodendroglioma grade II
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive Surgery
Excluded previous treatments
Chemotherapy Radiotherapy
14 recruiting sites
Hospices Civils de Lyon
Phase 3 Sarcoma and GIST #NCT07218926 #2025-522229-37-00
Required histologic types
GIST
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KIT PDGFRA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
GlaxoSmithKline
Phase 3 Lung cancer #NCT07185997 #2025-522151-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy Bispecific T-cell engager antibodies
7 recruiting sites
ArriVent BioPharma, Inc
Phase 3 Endometrial cancer #NCT07044336 #2024-518777-34-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
AstraZeneca
Phase 3 Prostate cancer #NCT06136650 #2023-504957-11-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Internal Vectorised Radiotherapy (IVR)
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lymphoma CLL & Richter's syndrome #NCT05254743 #2023-507699-38-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
10 recruiting sites
Loxo Oncology
Phase 3 Lymphoma #NCT06284122 #2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min < 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Kidney cancer #NCT07227402 #2024-517136-21-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Immunotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07318558
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required disease stage
Localized
Required HRD statuses
HRD Negative
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required previous treatments at advanced or metastatic stage
Chemotherapy
5 recruiting sites
Merck Sharp & Dohme LLC